Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Cancer Institute (U54 CA232561, U54 CA232561)
Rally Foundation (N/A)
Pediatric Cancer Research Foundation (N/A)
Children's Cancer Fund (N/A)
- License Information
-
More Information
Article History
Accepted: 11 October 2021
First Online: 8 March 2022
Declarations
:
: No human or animal studies were performed for the preparation of this manuscript.
: YC and ML have no conflict of interest to declare. MC is a consultant to Jazz Pharmaceuticals and NEKTAR and serve on the speaker bureau of Jazz Pharmaceuticals, Servier, Amgen, Sanofi and Sobi. DL reports stock ownership in Courier Therapeutics, has received consulting fees and stock options in Caribou Biosciences, and has received research grants, stock ownership, royalties, and consulting fees from Kiadis Pharma.
